Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparing pulsed field electroporation and radiofrequency ablation for the treatment of paroxysmal atrial fibrillation: design and rationale of the BEAT PAROX-AF randomized clinical trial

N. Erhard, E. Frison, J. Asselineau, B. Aouar, S. Boveda, H. Cochet, I. Deisenhofer, T. Deneke, A. Gimbert, J. Kautzner, S. Knecht, P. Maury, P. Neuzil, M. Rousset, D. Scherr, CW. Schneider, M. Sermesant, D. Wichterle, P. Jaïs, BEAT-AF Study group

. 2024 ; 26 (5) : . [pub] 20240502

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, protokol klinické studie, srovnávací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014013

Grantová podpora
945125 European Union's Horizon 2020 research and innovation

AIMS: Using thermal-based energy sources [radiofrequency (RF) energy/cryo energy] for catheter ablation is considered effective and safe when performing pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). However, treatment success remains limited and complications can occur due to the propagation of thermal energy into non-target tissues. We aim to compare pulsed field ablation (PFA) with RF ablation in terms of efficacy and safety for patients with drug-resistant paroxysmal AF. METHODS AND RESULTS: The BEAT PAROX-AF trial is a European multicentre, superiority, open-label randomized clinical trial in two parallel groups. A total of 292 participants were recruited in 9 high-volume European clinical centres in 5 countries. Patients with paroxysmal AF were randomized to PFA (FARAPULSE Endocardial Ablation System©, Boston Scientific) or RF using the CLOSE protocol with contact force sensing catheter (SmartTouch© catheter and CARTO© Biosense Webster). The primary endpoint will be the 1-year recurrence of atrial arrhythmia, and the major secondary safety endpoint will be the occurrence of acute (<7 days) procedure-related serious adverse events, or pulmonary vein stenosis, or atrio-oesophageal fistula up to 12 months. Additionally, five sub-studies investigate the effect of PFA on oesophageal safety, cerebral lesions, cardiac autonomic nervous system, durability of PVI as assessed during redo ablation procedures, and atrial and ventricular function. The study began on 27 December 2021 and concluded recruitment on 17 January 2024. Results will be available in mid-2025. CONCLUSION: The BEAT PAROX-AF trial aims to provide critical insights into the optimal treatment approach for patients with paroxysmal AF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014013
003      
CZ-PrNML
005      
20240905134051.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euae103 $2 doi
035    __
$a (PubMed)38646926
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Erhard, Nico $u Department of Electrophysiology, German Heart Center Munich, Lazarettstraße 36, 80636 Munich, Technical University of Munich, Munich, Germany
245    10
$a Comparing pulsed field electroporation and radiofrequency ablation for the treatment of paroxysmal atrial fibrillation: design and rationale of the BEAT PAROX-AF randomized clinical trial / $c N. Erhard, E. Frison, J. Asselineau, B. Aouar, S. Boveda, H. Cochet, I. Deisenhofer, T. Deneke, A. Gimbert, J. Kautzner, S. Knecht, P. Maury, P. Neuzil, M. Rousset, D. Scherr, CW. Schneider, M. Sermesant, D. Wichterle, P. Jaïs, BEAT-AF Study group
520    9_
$a AIMS: Using thermal-based energy sources [radiofrequency (RF) energy/cryo energy] for catheter ablation is considered effective and safe when performing pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). However, treatment success remains limited and complications can occur due to the propagation of thermal energy into non-target tissues. We aim to compare pulsed field ablation (PFA) with RF ablation in terms of efficacy and safety for patients with drug-resistant paroxysmal AF. METHODS AND RESULTS: The BEAT PAROX-AF trial is a European multicentre, superiority, open-label randomized clinical trial in two parallel groups. A total of 292 participants were recruited in 9 high-volume European clinical centres in 5 countries. Patients with paroxysmal AF were randomized to PFA (FARAPULSE Endocardial Ablation System©, Boston Scientific) or RF using the CLOSE protocol with contact force sensing catheter (SmartTouch© catheter and CARTO© Biosense Webster). The primary endpoint will be the 1-year recurrence of atrial arrhythmia, and the major secondary safety endpoint will be the occurrence of acute (<7 days) procedure-related serious adverse events, or pulmonary vein stenosis, or atrio-oesophageal fistula up to 12 months. Additionally, five sub-studies investigate the effect of PFA on oesophageal safety, cerebral lesions, cardiac autonomic nervous system, durability of PVI as assessed during redo ablation procedures, and atrial and ventricular function. The study began on 27 December 2021 and concluded recruitment on 17 January 2024. Results will be available in mid-2025. CONCLUSION: The BEAT PAROX-AF trial aims to provide critical insights into the optimal treatment approach for patients with paroxysmal AF.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x chirurgie $x patofyziologie $x diagnóza $x terapie $7 D001281
650    12
$a katetrizační ablace $x metody $7 D017115
650    _2
$a výsledek terapie $7 D016896
650    _2
$a venae pulmonales $x chirurgie $7 D011667
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a recidiva $7 D012008
650    _2
$a lidé středního věku $7 D008875
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Frison, Eric $u University Bordeaux, INSERM, Institut Bergonié, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France $1 https://orcid.org/0000000158441886
700    1_
$a Asselineau, Julien $u University Bordeaux, INSERM, Institut Bergonié, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France
700    1_
$a Aouar, Besma $u University Bordeaux, INSERM, Institut Bergonié, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France $1 https://orcid.org/0009000773019094
700    1_
$a Boveda, Serge $u Heart Rhythm Department, Clinique Pasteur, Toulouse, France $1 https://orcid.org/0000000212807042
700    1_
$a Cochet, Hubert $u IHU LIRYC, University Bordeaux, CHU Bordeaux, Bordeaux, France $1 https://orcid.org/0000000177725331
700    1_
$a Deisenhofer, Isabel $u Department of Electrophysiology, German Heart Center Munich, Lazarettstraße 36, 80636 Munich, Technical University of Munich, Munich, Germany $1 https://orcid.org/0000000158266846
700    1_
$a Deneke, Thomas $u Department of Cardiology, Cardiovascular Center Bad Neustadt/Saale, Bad Neustadt an der Saale, Germany $1 https://orcid.org/0000000313791684
700    1_
$a Gimbert, Anne $u Clinical Research and Innovation Department, CHU Bordeaux, Bordeaux, France
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia $1 https://orcid.org/0000000216326182 $7 xx0037112
700    1_
$a Knecht, Sebastien $u Department of Cardiology, AZ Sint-Jan Hospital, Bruges, Belgium $1 https://orcid.org/0000000345000146
700    1_
$a Maury, Philippe $u Department of Cardiology, University Hospital Rangueil, Toulouse, France $1 https://orcid.org/0000000248001841
700    1_
$a Neuzil, Petr $u Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia $1 https://orcid.org/0000000343348165
700    1_
$a Rousset, Marine $u Clinical Research and Innovation Department, CHU Bordeaux, Bordeaux, France $1 https://orcid.org/0000000231026866
700    1_
$a Scherr, Daniel $u Division of Cardiology, Medical University of Graz, Graz, Austria $1 https://orcid.org/0000000158685493
700    1_
$a Schneider, Christopher W $u Department of Electrophysiology, Boston Scientific Corporation, St Paul, MN, USA
700    1_
$a Sermesant, Maxime $u IHU LIRYC, University Bordeaux, INSERM, CRCTB, U 1045, Bordeaux, France $u Inria, Université Côte d'Azur, Epione Team, Sophia Antipolis, France $1 https://orcid.org/0000000262568350
700    1_
$a Wichterle, Dan $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia $1 https://orcid.org/0000000204485143 $7 xx0101417
700    1_
$a Jaïs, Pierre $u IHU LIRYC, University Bordeaux, CHU Bordeaux, Bordeaux, France $1 https://orcid.org/0000000247007811
710    2_
$a BEAT-AF Study group
773    0_
$w MED00149837 $t Europace $x 1532-2092 $g Roč. 26, č. 5 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38646926 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134045 $b ABA008
999    __
$a ok $b bmc $g 2143668 $s 1225879
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 5 $e 20240502 $i 1532-2092 $m Europace $n Europace $x MED00149837
GRA    __
$a 945125 $p European Union's Horizon 2020 research and innovation
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace